Formycon Achieves Key Milestones in Q1 2025 Amid Challenging Conditions

Formycon AG reported a robust operational performance in Q1 2025 marked by key product approvals and strategic partnerships. The company secured market approvals for its biosimilar FYB203 (Aflibercept) in Europe and the UK, collaborating with Teva Pharmaceuticals and Lotus Pharmaceutical for wider distribution. Additionally, the FYB202/Otulfi® (Ustekinumab) launch by partner Fresenius Kabi in the US and Europe generated substantial initial revenues, reflecting its market potential.

The financial results aligned with expectations despite macroeconomic challenges. Revenue was €5.3 million, down from €17.7 million in the previous year due to a shift in revenue mix. EBITDA was reported at €-13.2 million, influenced by increased development expenses and the strategic pause in the US commercialization of FYB201.

Formycon reaffirmed its full-year guidance, anticipating sustainable growth and a positive EBITDA by 2026. With its strategic partnerships and product launches, the company remains positioned for continued expansion in the biosimilars market.